"Glycine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
| Descriptor ID |
D005998
|
| MeSH Number(s) |
D12.125.481
|
| Concept/Terms |
Glycine- Glycine
- Aminoacetic Acid
- Acid, Aminoacetic
|
Below are MeSH descriptors whose meaning is more general than "Glycine".
Below are MeSH descriptors whose meaning is more specific than "Glycine".
This graph shows the total number of publications written about "Glycine" by people in this website by year, and whether "Glycine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 |
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 4 | 5 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 4 | 4 |
| 2005 | 1 | 5 | 6 |
| 2006 | 1 | 5 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 4 | 2 | 6 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycine" by people in Profiles.
-
Sex Differences in Response to Diet Enriched With Glutathione Precursors in the Aging Heart. J Gerontol A Biol Sci Med Sci. 2025 Jan 16; 80(2).
-
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv. 2024 08 13; 8(15):4209-4220.
-
SART3 reads methylarginine-marked glycine- and arginine-rich motifs. Cell Rep. 2024 07 23; 43(7):114459.
-
Gastrointestinal toxicities of proteasome inhibitor therapy. J Cancer Res Clin Oncol. 2024 Jul 05; 150(7):334.
-
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. Am J Hematol. 2024 Sep; 99(9):1746-1756.
-
Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome. Curr Oncol Rep. 2024 Jul; 26(7):762-772.
-
How hydrophobicity, side chains, and salt affect the dimensions of disordered proteins. Protein Sci. 2024 May; 33(5):e4986.
-
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. Eur J Haematol. 2024 Aug; 113(2):190-200.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
The impact of obesity-associated glycine deficiency on the elimination of endogenous and exogenous metabolites via the glycine conjugation pathway. Front Endocrinol (Lausanne). 2024; 15:1343738.